TScan Therapeutics Inc
NASDAQ:TCRX
Income Statement
Earnings Waterfall
TScan Therapeutics Inc
Income Statement
TScan Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
4
|
4
|
4
|
4
|
4
|
4
|
3
|
3
|
3
|
|
| Revenue |
1
N/A
|
3
+186%
|
6
+91%
|
8
+36%
|
10
+25%
|
11
+10%
|
12
+11%
|
13
+8%
|
14
+2%
|
17
+28%
|
16
-5%
|
17
+3%
|
21
+24%
|
15
-30%
|
12
-18%
|
9
-23%
|
3
-70%
|
4
+57%
|
7
+57%
|
8
+21%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(27)
|
(32)
|
(40)
|
(50)
|
(59)
|
(68)
|
(74)
|
(75)
|
(80)
|
(91)
|
(99)
|
(108)
|
(115)
|
(117)
|
(124)
|
(129)
|
(138)
|
(145)
|
(152)
|
(158)
|
|
| Selling, General & Administrative |
(7)
|
(8)
|
(10)
|
(12)
|
(14)
|
(16)
|
(18)
|
(19)
|
(20)
|
(24)
|
(25)
|
(26)
|
(26)
|
(26)
|
(27)
|
(28)
|
(30)
|
(32)
|
(33)
|
(33)
|
|
| Research & Development |
(21)
|
(24)
|
(30)
|
(38)
|
(45)
|
(52)
|
(56)
|
(57)
|
(60)
|
(67)
|
(74)
|
(81)
|
(88)
|
(91)
|
(97)
|
(100)
|
(107)
|
(112)
|
(117)
|
(122)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(2)
|
|
| Operating Income |
(26)
N/A
|
(29)
-9%
|
(34)
-18%
|
(42)
-26%
|
(49)
-15%
|
(57)
-17%
|
(61)
-8%
|
(62)
-1%
|
(67)
-7%
|
(73)
-10%
|
(83)
-13%
|
(91)
-10%
|
(93)
-3%
|
(102)
-9%
|
(112)
-9%
|
(119)
-7%
|
(135)
-13%
|
(141)
-4%
|
(145)
-3%
|
(150)
-3%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
4
|
5
|
7
|
8
|
8
|
9
|
9
|
7
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(26)
N/A
|
(29)
-9%
|
(34)
-18%
|
(42)
-26%
|
(49)
-15%
|
(57)
-17%
|
(61)
-8%
|
(62)
-1%
|
(66)
-7%
|
(73)
-10%
|
(82)
-12%
|
(88)
-8%
|
(89)
-1%
|
(97)
-9%
|
(104)
-8%
|
(111)
-7%
|
(127)
-15%
|
(131)
-3%
|
(137)
-4%
|
(143)
-4%
|
|
| Net Income | |||||||||||||||||||||
| Income from Continuing Operations |
(26)
|
(29)
|
(34)
|
(42)
|
(49)
|
(57)
|
(61)
|
(62)
|
(66)
|
(73)
|
(82)
|
(88)
|
(89)
|
(97)
|
(104)
|
(111)
|
(127)
|
(131)
|
(137)
|
(143)
|
|
| Net Income (Common) |
(26)
N/A
|
(29)
-9%
|
(34)
-18%
|
(42)
-26%
|
(49)
-15%
|
(57)
-17%
|
(61)
-8%
|
(62)
-1%
|
(66)
-7%
|
(73)
-10%
|
(82)
-12%
|
(88)
-8%
|
(89)
-1%
|
(97)
-9%
|
(104)
-8%
|
(111)
-7%
|
(127)
-15%
|
(131)
-3%
|
(137)
-4%
|
(143)
-4%
|
|
| EPS (Diluted) |
-1.11
N/A
|
-1.21
-9%
|
-1.42
-17%
|
-1.79
-26%
|
-2.06
-15%
|
-2.39
-16%
|
-2.54
-6%
|
-2.57
-1%
|
-2.75
-7%
|
-3.01
-9%
|
-1.72
+43%
|
-0.93
+46%
|
-1.36
-46%
|
-1.02
+25%
|
-0.92
+10%
|
-0.93
-1%
|
-1.14
-23%
|
-1.01
+11%
|
-1.05
-4%
|
-1.09
-4%
|
|